StreetInsider.com News Articles

Evercore ISI Starts Tenax Therapeutics (TENX) at Outperform

Wed, 22 Jul 2026 08:16:54 -0400

(Updated - July 22, 2026 8:16 AM EDT)

Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Tenax Therapeutics (NASDAQ: TENX) with a Outperform rating and a price target of $39.00.

The analyst commented: "This is not a conviction call for us. There’s not enough data for this to be a conviction call for anyone. That’s why the stock is only $1B mkt cap in the context of massive potential upside driven by the huge unmet need in PH-HFpEF. But we spent a lot of time digging in and walked away thinking … this trial has a real shot at working. We model

Evercore ISI Starts Tenax Therapeutics (TENX) at Outperform

Wed, 22 Jul 2026 08:16:54 -0400

(Updated - July 22, 2026 8:16 AM EDT)

Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Tenax Therapeutics (NASDAQ: TENX) with a Outperform rating and a price target of $39.00.

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: MILLENNIUM MANAGEMENT LLC

Fri, 17 Jul 2026 17:59:00 -0400

si-local-file:///var/storage/secattach/20260717/26785350.html

Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: MILLENNIUM MANAGEMENT LLC

Fri, 17 Jul 2026 17:59:00 -0400

si-local-file:///var/storage/secattach/20260717/26785350.html

Form 4 TENAX THERAPEUTICS, INC. For: Jul 13 Filed by: Giordano Christopher Thomas

Tue, 14 Jul 2026 19:29:00 -0400

si-local-file:///var/storage/secattach/20260714/26769391.html

Form 4 TENAX THERAPEUTICS, INC. For: Jul 13 Filed by: Giordano Christopher Thomas

Tue, 14 Jul 2026 19:29:00 -0400

si-local-file:///var/storage/secattach/20260714/26769391.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745697.html

Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745697.html

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly hired by the Company in various accounting, clinical operations, and CMC/product development roles.

The employees received or will receive, in the aggregate, non-qualified stock options to purchase 160,000 shares of the Company's common stock with an exercise price equal to

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The employees received or will receive, in the aggregate, non-qualified stock options to purchase 160,000 shares of the Company's common stock with an exercise price equal to

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The employees received or will receive, in the aggregate, non-qualified stock options to purchase 160,000 shares of the Company's common stock with an exercise price equal to

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The employees received or will receive, in the aggregate, non-qualified stock options to purchase 160,000 shares of the Company's common stock with an exercise price equal to

Form 8-K TENAX THERAPEUTICS, INC. For: Jul 02

Thu, 02 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26724211.html

Form 8-K TENAX THERAPEUTICS, INC. For: Jul 02

Thu, 02 Jul 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26724211.html

Tenax Therapeutics to present LEVEL trial data at ESC Congress

Thu, 02 Jul 2026 07:00:42 -0400

Tenax Therapeutics, Inc. (Nasdaq: TENX) announced that results from its Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, scheduled for August 28-31 in Munich, Germany.

The presentation, titled "Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial," is scheduled for August 29, 2026, at 11:15 a.m. CEST. Professor Sanjiv Shah, MD, of Northwestern University will serve as presenter.

According to a press release, the company submitted an abstract in anticipation of receiving topline results in time for

Tenax Therapeutics to present LEVEL trial data at ESC Congress

Thu, 02 Jul 2026 07:00:42 -0400

According to a press release, the company submitted an abstract in anticipation of receiving topline results in time for

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Thu, 02 Jul 2026 07:00:00 -0400